Skip to earnings analysis
← Back to feed
HUM FY2025 Q4 SOFTENING

Humana Inc. earnings call

Feb 11, 2026 · 08:00 ET Celeste MillayDavid DittenfossGeorge
Buzzberg read

Expects 2026 individual MA membership growth of ~25%

Humana delivered solid 2025 results but guided to a sharply lower 2026 EPS due to a massive STARS headwind and slightly negative individual MA margins, even as it executes on a member growth strategy. Management remains confident in doubling MA margins when normalizing for STARS and in its path to 2028 earnings potential, while flagging higher-than-usual conservatism in guidance. 2025 adjusted EPS of $17.14, in line with expectations and above initial guidance, with insurance MLR at 90.4% slightly better than guide.

Buzzberg read Expects 2026 individual MA membership growth of ~25% Humana delivered solid 2025 results but guided to a sharply lower 2026 EPS due to a massive STARS headwind and slightly negative individual MA margins, even as it executes on a member growth strategy. Management remains confident in doubling MA margins when normalizing for STARS and in its path to 2028 earnings potential, while flagging higher-than-usual conservatism in guidance. 2025 adjusted EPS of $17.14, in line with expectations and above initial guidance, with insurance MLR at 90.4% slightly better than guide. Read full analysisCollapse analysis

Humana delivered solid 2025 results but guided to a sharply lower 2026 EPS due to a massive STARS headwind and slightly negative individual MA margins, even as it executes on a member growth strategy. Management remains confident in doubling MA margins when normalizing for STARS and in its path to 2028 earnings potential, while flagging higher-than-usual conservatism in guidance. 2025 adjusted EPS of $17.14, in line with expectations and above initial guidance, with insurance MLR at 90.4% slightly better than guide.

  • 2026 EPS guided to at least $9, down significantly, driven by the $3.5B net STARS headwind; individual MA margins are expected to be slightly below break-even.
  • Strong AEP growth of ~20% (1M members) with improved retention and a mix shift toward switchers; 2026 membership expected to grow ~25% and be enterprise-accretive.
  • Management emphasizes doubling individual MA margins in 2026 when normalizing for STARS, driven by clinical excellence and operating efficiency efforts.
Revenue $32.515B reported
EPS $-3.96 reported
Gross margin 11.67% reported
Op margin -3.15% reported

What changed this quarter

01
Membership Growth

Expects 2026 individual MA membership growth of ~25%

Humana delivered solid 2025 results but guided to a sharply lower 2026 EPS due to a massive STARS headwind and slightly negative individual MA margins, even as it executes on a member growth strategy. Management remains confident in doubling MA margins when normalizing for…

02
STARS

2026 STARS headwind net of mitigation is ~$3.5 billion

2025 adjusted EPS of $17.14, in line with expectations and above initial guidance, with insurance MLR at 90.4% slightly better than guide.

03
Margin

New members expected to be enterprise accretive in 2026

2026 EPS guided to at least $9, down significantly, driven by the $3.5B net STARS headwind; individual MA margins are expected to be slightly below break-even.

04
Margin

Individual MA margins slightly below break-even in 2026

Strong AEP growth of ~20% (1M members) with improved retention and a mix shift toward switchers; 2026 membership expected to grow ~25% and be enterprise-accretive.

Demand & capex

Demand

Bookings & conversion

Guidance points to a significant decline in EPS for 2026, driven by the large STARS headwind and slightly negative individual MA margins, though management emphasizes a doubling of margins when normalizing for STARS and sees growth as accretive to the enterprise.

Capex

Investment and capacity

Management discussed capital efficiency efforts to fund membership growth, including optimizing legal entity structures, reinsurance, selling non-core assets, and managing capital deployment. They expect statutory capital requirements to increase by less than 20% despite 40% premium growth, offsetting over $3 billion in capital needs.

Tone · Confident

Management expressed confidence in membership growth, operational capacity, and progress toward STARS and margin targets, while acknowledging and adapting to funding environment pressures.

Supply-chain alpha

A1

Humana gained ~1 million net new MA members (20% AEP growth) with a 500 bps retention improvement; 70% of new sales were switchers from competitors, but Humana only absorbed 12% of competitor plan-exit members — less than its market share, implying rivals retained more of their exiting members or other competitors captured a larger share.

“We did not have a high percentage of members impacted by competitor plan exits. we absorbed approximately 12% of these members. That is notably less than our market share.”
Jim Recton
A2

Humana's 2026 EPS outlook embeds a higher-than-typical level of conservatism, including a haircut on top of already conservative assumptions like MRA, to account for the dynamic environment.

“the level of conservatism in our initial guide is higher than typical to account for the dynamic environment.”
Celeste Millay
A3

The $3.5B STARS headwind for 2026 is larger than prior discussions due to membership growth; higher retention kept more members on 3.5-star contracts, and ~30% of new sales were on contracts rated below 4 stars for BY26, capping near-term margin improvement.

“When calculating the headwind for 26, it is important to keep the membership and revenue growth in mind, which is why the number is larger than what we have previously discussed with you.”
Celeste Millay

Forward guidance

SofteningGuidance tone
Forward guidance
MetricPeriodRangeMidpointStatus
EPSFY2026$9.00$9.00GUIDED

Company read-throughs

+46.7%
since call
$272.44$399.74
+29.2%
since call
$75.00$96.94
Supply chainSupply-chain alpha

Humana gained ~1 million net new MA members (20% AEP growth) with a 500 bps retention improvement; 70% of new sales were switchers from competitors, but Humana only absorbed 12% of competitor plan-exit members — less than its market share, implying rivals retained more of their exiting members or other competitors captured a larger share. — This suggests competitor plan exits (e.g., from UNH or CVS) may have driven less churn benefit to Humana than its market share would imply, potentially indicating those competitors found ways to retain more of their exiting members or other rivals captured more.